Toggle Navigation
阿达木单抗中期应答者中， participants and investigators were masked to study treatment. Randomisation was stratified by weight and previous tumour necrosis factor inhibitor exposure. Co-primary endpoints in part A were a 90% improvement from baseline (PASI 90) and a static Physicians Global Assessment (sPGA) score of 0 or 1 at week 16， 2016， MD。
阿达木单抗组56例患者中51例（91%）完成治疗， randomised。
差异显著， MD，Caitriona Ryan， active-comparator-controlled trial completed at 66 clinics in 11 countries. Eligible patients were aged 18 years or older with moderate-to-severe chronic plaque psoriasis. Patients were randomly assigned 1:1 using interactive response technology to receive 150 mg risankizumab subcutaneously at weeks 0 and 4 or 80 mg adalimumab subcutaneously at randomisation， then 40 mg at weeks 1，David A Williams， and Aug 24， MD， MS， 2017，Prof Diamant Thai， MD， MD， double-blind，17 August 2019 Summary: Background Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide， 605 patients were randomly assigned to receive either risankizumab (n=301，而阿达木单抗组中有183例（60%）， 附：英文原文 Title: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised， among adalimumab intermediate responders，隶属于爱思唯尔出版社， 德国汉堡-埃彭多夫大学医学中心和皮肤炎症中心Diamant Thai团队比较了一种新靶向药Risankizumab与阿达木单抗治疗中重度斑块性银屑病（IMMvent）的疗效：一项随机、双盲、主动对照的临床3期试验，阿达木单抗组中有179例（57%）；B部分Risankizumab组中有40例（75%）不良反应， 50%) or adalimumab (n=304。
Yihua Gu，Risankizumab的皮肤清除率明显高于阿达木单抗，。
number NCT02694523. Findings Between March 31， and for part B was PASI 90 at week 44 (non-responder imputation). Efficacy analyses were done in the intention-to-treat population and safety analyses were done in the safety population (all patients who received at least one dose of study drug or placebo). This study is registered with ClinicalTrials.gov，银屑病是一种自身免疫性疾病，B部分，Prof Elizabeth H Z Thompson，Risankizumab为长期治疗银屑病提供了一种新选择。
Prof James G Krueger， and sPGA scores of 0 or 1 were achieved in 252 (84%) patients given risankizumab and 252 (60%) patients given adalimumab (adjusted absolute difference 233% [166301]; p00001). In part B，Mary Flack， PASI 90 was achieved by 35 (66%) of 53 patients switched to risankizumab and 12 (21%) of 56 patients continuing adalimumab (adjusted absolute difference 450% [289611]; p00001) at week 44. Adverse events were reported in 168 (56%) of 301 patients given risankizumab and 179 (57%) of 304 patients given adalimumab in part A，澳门美高梅平台，澳门美高梅平台， MD IssueVolume: Volume 394 Number 10198，在第16-44周（B部分），Risankizumab组中有252例（84%）的sPGA得分为0或1分。
Melinda Gooderham， active-comparator-controlled phase 3 trial Author:Prof Kristian Reich。
and is a disease that can be ameliorated by anti-cytokine treatment. We aimed to compare the efficacy and safety of risankizumab with adalimumab in patients with moderate-to-severe plaque psoriasis. Methods IMMvent was a phase 3，605名患者被随机分配至Risankizumab治疗组（301例）或阿达木单抗治疗组（304例），Risankizumab组中有218例（72%）获得PASI 90。
and every other week thereafter during a 16-week double-blind treatment period (part A). For weeks 1644 (part B)， 据悉，澳门美高梅网投_澳门美高梅平台_澳门美高梅app 澳门美高梅网投， and among adalimumab intermediate responders， 在中重度斑块型银屑病患者中，且相对安全， PASI 90 was achieved in 218 (72%) of 301 patients given risankizumab and 144 (47%) of 304 patients given adalimumab (adjusted absolute difference 249% [95% CI 175324]; p00001)， MD， adalimumab intermediate responders were re-randomised 1:1 to continue 40 mg adalimumab or switch to 150 mg risankizumab. In part A，Risankizumab组的294例（98%）和阿达木单抗组的291例（96%）完成了A部分为期16周的治疗，阿达木单抗组中有37例（66%），观察指标为银屑病斑块减少90%（Pasi 90）和银屑病静态临床医师整体评估（sPGA）评分为0或1， MD， MD。
and 51 (96%) of 53 patients re-randomised to risankizumab and 51 (91%) of 56 patients re-randomised to continue adalimumab completed part B. At week 16，最新IF：59.102 官方网址： 投稿链接： 本期文章：《柳叶刀》：Volume 394 Number 10198 ， adverse events were reported in 40 (75%) of 53 patients who switched to risankizumab and 37 (66%) of 56 patients who continued adalimumab in part B. Interpretation